Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077662 · ClinicalTrials.gov registry record
A Prospective, Observational Study in Patients With Late-Onset Pompe Disease
A clinical trial, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- 61
- Enrollment target
NCT00077662: Completed study, sponsored by Genzyme, a Sanofi Company.
NCT00077662 is a clinical trial that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00077662 has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- 61 participants
- Enrollment target
Study Summary
Pompe disease (also known as glycogen storage disease type II, "GSD-II") is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. This study is being conducted to collect prospective, observational data on patients with late-onset Pompe disease. Approximately 60 subjects with late-onset Pompe disease will be enrolled.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2004-03 |
| Est. Completion | 2006-01 |
What the finished NCT00077662 record still lists
NCT00077662 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 61 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00077662 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00077662 about?
NCT00077662 is a clinical study titled "A Prospective, Observational Study in Patients With Late-Onset Pompe Disease". Pompe disease (also known as glycogen storage disease type II, "GSD-II") is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lyso...
What is the current status of trial NCT00077662?
This trial is currently completed. The enrollment target is 61 participants. The study started on 2004-03. Estimated completion is 2006-01.
Who is sponsoring clinical trial NCT00077662?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia